• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.复发性利福平敏感结核病的大剂量一线治疗方案
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1578-1579. doi: 10.1164/rccm.202001-0201LE.
2
Reply to Decroo : High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.回复德克鲁：复发性利福平敏感结核病的大剂量一线治疗方案
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1579-1580. doi: 10.1164/rccm.202002-0359LE.
3
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.采用异烟肼、利福平、乙胺丁醇和吡嗪酰胺治疗耐异烟肼结核病6个月。
Int J Tuberc Lung Dis. 2002 Nov;6(11):952-8.
4
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.耐多药结核病项目中高剂量利福平、异烟肼和吡嗪酰胺治疗的中敏剂量依赖性折点。
Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.
5
Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.新生儿和婴儿结核病：流行病学、发病机制、临床表现、诊断及管理问题
Paediatr Drugs. 2005;7(4):219-34. doi: 10.2165/00148581-200507040-00002.
6
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.在一个耐药结核病发病率较低的国家，表型上对利福平敏感的结核分枝杆菌分离株中出现有争议的 rpoB 突变。
BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z.
7
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.在抗结核治疗的前 8 周，莫西沙星、贝达喹啉（PA-824）和吡嗪酰胺联合使用的疗效和安全性：一项在药物敏感性或耐药性肺结核患者中进行的 2b 期、开放标签、部分随机试验。
Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.
8
Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.2015-2019 年巴基斯坦利福平耐药和敏感的肺及肺外结核患者的异烟肼耐药谱及相关左氧氟沙星和吡嗪酰胺耐药情况：一项基于实验室的监测研究。
PLoS One. 2020 Sep 23;15(9):e0239328. doi: 10.1371/journal.pone.0239328. eCollection 2020.
9
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.2012-2014 年秘鲁异烟肼单耐药结核病的治疗结果。
PLoS One. 2018 Dec 4;13(12):e0206658. doi: 10.1371/journal.pone.0206658. eCollection 2018.
10
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].[耐异烟肼或耐利福平结核病的特征及治疗结果]
Kekkaku. 2003 Oct;78(10):611-7.

引用本文的文献

1
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach.定量测量结核分枝杆菌中的抗生素耐药性，揭示了目标基因方法中耐药性和敏感性的遗传决定因素。
Nat Commun. 2024 Jan 12;15(1):488. doi: 10.1038/s41467-023-44325-5.
2
Quantitative measurement of antibiotic resistance in reveals genetic determinants of resistance and susceptibility in a target gene approach.抗生素耐药性的定量测量揭示了基于靶基因方法的耐药性和敏感性的遗传决定因素。
Res Sq. 2023 Oct 2:rs.3.rs-3378915. doi: 10.21203/rs.3.rs-3378915/v1.
3
Genome-wide association studies of global Mycobacterium tuberculosis resistance to 13 antimicrobials in 10,228 genomes identify new resistance mechanisms.全基因组关联研究发现全球结核分枝杆菌对 13 种抗微生物药物的耐药性与 10228 个基因组中的新耐药机制有关。
PLoS Biol. 2022 Aug 9;20(8):e3001755. doi: 10.1371/journal.pbio.3001755. eCollection 2022 Aug.
4
A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.一项关于晚期肺结核治疗试验终点定义的系统评价。
Trials. 2021 Aug 3;22(1):515. doi: 10.1186/s13063-021-05388-1.
5
Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya.肯尼亚马查科斯县既往治疗和新发病例一线结核病治疗结局比较：一项回顾性研究。
Int Health. 2021 Apr 27;13(3):272-280. doi: 10.1093/inthealth/ihaa051.

本文引用的文献

1
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.不同异烟肼剂量对耐多药结核病的早期杀菌活性（事后回顾）：一项随机、开放标签的临床试验
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1416-1424. doi: 10.1164/rccm.201910-1960OC.
2
Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.构建结核病治疗方案的原则：核心药物和辅助药物的作用和定义。
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660.
3
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.高剂量利福平、莫西沙星和SQ109治疗结核病：一项多组、多阶段随机对照试验。
Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.
4
Rifampin drug resistance tests for tuberculosis: challenging the gold standard.利福平耐药结核病检测：挑战金标准。
J Clin Microbiol. 2013 Aug;51(8):2633-40. doi: 10.1128/JCM.00553-13. Epub 2013 Jun 12.
5
A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.高剂量异烟肼辅助治疗耐多药结核病的随机对照试验。
Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45.

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.

作者信息

Decroo Tom, de Jong Bouke C, Piubello Alberto, Souleymane Mahamadou Bassirou, Lynen Lutgarde, Van Deun Armand

机构信息

Institute of Tropical MedicineAntwerp, Belgium.

Research Foundation FlandersBrussels, Belgium.

出版信息

Am J Respir Crit Care Med. 2020 Jun 15;201(12):1578-1579. doi: 10.1164/rccm.202001-0201LE.

DOI:10.1164/rccm.202001-0201LE
PMID:32130864
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7301730/
Abstract
摘要